文献速递胸部肿瘤

布格替尼在阿来替尼耐药ALK阳性NSCLC中的疗效

Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.
PubMed 文献 · J Thorac Oncol · 2018-06-20

在18例可测量病灶患者中,确认客观缓解3例(17%),9例(50%)疾病稳定。中位无进展生存期4.4个月(95%CI:1.8-5.6个月),中位治疗持续时间5.7个月(95%CI:1.8-6.2个月)。布格替尼在阿来替尼耐药患者中临床活性有限。

要点

  • 布格替尼在阿来替尼耐药ALK阳性NSCLC中客观缓解率17%(3/18)。
  • 中位无进展生存期4.4个月(95%CI:1.8-5.6个月)。
  • 阿来替尼耐药后活检检出ALK I1171X或V1180L突变者可能对布格替尼有反应。

核心结论

  • 布格替尼在阿来替尼耐药的ALK阳性NSCLC中临床活性有限。

主要发现

  • 18例可测量病灶患者中确认客观缓解3例(17%),9例(50%)疾病稳定。
  • 中位无进展生存期4.4个月(95%CI:1.8-5.6个月),中位治疗持续时间5.7个月(95%CI:1.8-6.2个月)。
  • 9例阿来替尼后/布格替尼前活检患者中,5例检出ALK I1171X或V1180L突变,其中1例确认部分缓解、3例疾病稳定。
  • 1例检出ALK G1202R突变,最佳总体疗效为疾病进展。

临床怎么用

  • 阿来替尼耐药后布格替尼疗效有限,需根据耐药突变选择后续治疗。
  • 阿来替尼耐药后建议再活检明确ALK耐药突变以指导治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib recently showed superior efficacy compared to the first-generation ALK inhibitor crizotinib in advanced ALK-rearranged NSCLC, establishing alectinib as the new standard first-line therapy. Brigatinib, another second-generation ALK inhibitor, has shown substantial activity in patients with crizotinib-refractory ALK-positive NSCLC; however, its activity in the alectinib-refractory setting is unknown. METHODS: A multicenter, retrospective study was performed at three institutions. Patients were eligible if they had advanced, alectinib-refractory ALK-positive NSCLC and were treated with brigatinib. Medical records were reviewed to determine clinical outcomes. RESULTS: Twenty-two patients were eligible for this study. Confirmed objective responses to brigatinib were observed in 3 of 18 patients (17%) with measurable disease. Nine patients (50%) had stable disease on brigatinib. The median progression-free survival was 4.4 months (95% confidence interval [CI]: 1.8-5.6 months) with a median duration of treatment of 5.7 months (95% CI: 1.8-6.2 months). Among 9 patients in this study who underwent post-alectinib/pre-brigatinib biopsies, 5 had an ALK I1171X or V1180L resistance mutation; of these, 1 had a confirmed partial response and 3 had stable disease on brigatinib. One patient had an ALK G1202R mutation in a post-alectinib/pre-brigatinib biopsy, and had progressive disease as the best overall response to brigatinib. CONCLUSIONS: Brigatinib has limited clinical activity in alectinib-refractory ALK-positive NSCLC. Additional studies are needed to establish biomarkers of response to brigatinib and to identify effective therapeutic options for alectinib-resistant ALK-positive NSCLC patients.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Lin JJ, Zhu VW, Schoenfeld AJ, et al. Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. J Thorac Oncol. 2018. PMID: 29935304. doi:10.1016/j.jtho.2018.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。